iTonic Holdings Ltd.
iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment p… Read more
iTonic Holdings Ltd. (ITOC) - Net Assets
Latest net assets as of June 2025: $4.73 Million USD
Based on the latest financial reports, iTonic Holdings Ltd. (ITOC) has net assets worth $4.73 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.11 Million) and total liabilities ($382.60K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.73 Million |
| % of Total Assets | 92.52% |
| Annual Growth Rate | 86.41% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 925.22 |
iTonic Holdings Ltd. - Net Assets Trend (2021–2024)
This chart illustrates how iTonic Holdings Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for iTonic Holdings Ltd. (2021–2024)
The table below shows the annual net assets of iTonic Holdings Ltd. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $6.18 Million | +1919.35% |
| 2023-12-31 | $306.27K | -44.95% |
| 2022-12-31 | $556.32K | -41.71% |
| 2021-12-31 | $954.34K | -- |
Equity Component Analysis
This analysis shows how different components contribute to iTonic Holdings Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 174.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.43K | 0.02% |
| Other Comprehensive Income | $41.51K | 0.67% |
| Other Components | $6.66 Million | 107.76% |
| Total Equity | $6.18 Million | 100.00% |
iTonic Holdings Ltd. Competitors by Market Cap
The table below lists competitors of iTonic Holdings Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fecto Cement Ltd
KAR:FECTC
|
$3.08K |
|
ATLANTIC PETROLEUM
BE:B3W
|
$3.08K |
|
888 HOLDINGS (C8V.SG)
STU:C8V
|
$3.08K |
|
BRITISH AMERICAN TOBACCO ZIMBABWE HOLDINGS LIMITED
XZIM:BAT
|
$3.09K |
|
Pebble Beach Systems Group PLC
LSE:PEB
|
$3.08K |
|
Hotland Yantian Port Warehouse Logistics
SHE:180301
|
$3.08K |
|
3P Land Holdings Limited
NSE:3PLAND
|
$3.08K |
|
International Company For Fertilizers & Chemicals
EGX:ICFC
|
$3.08K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in iTonic Holdings Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 306,272 to 6,184,703, a change of 5,878,431 (1919.3%).
- Net loss of 660,588 reduced equity.
- New share issuances of 7,795,642 increased equity.
- Other comprehensive income decreased equity by 5,116.
- Other factors decreased equity by 1,251,507.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-660.59K | -10.68% |
| Share Issuances | $7.80 Million | +126.05% |
| Other Comprehensive Income | $-5.12K | -0.08% |
| Other Changes | $-1.25 Million | -20.24% |
| Total Change | $- | 1919.35% |
Book Value vs Market Value Analysis
This analysis compares iTonic Holdings Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.63x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 4.69x to 0.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $0.07 | $0.31 | x |
| 2022-12-31 | $0.04 | $0.31 | x |
| 2023-12-31 | $0.02 | $0.31 | x |
| 2024-12-31 | $0.49 | $0.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently iTonic Holdings Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -147.39%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.09x
- Recent ROE (-10.68%) is above the historical average (-13.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 20.17% | 27.39% | 0.53x | 1.39x | $97.03K |
| 2022 | 15.10% | 12.35% | 0.48x | 2.52x | $28.35K |
| 2023 | -78.76% | -38.37% | 0.39x | 5.30x | $-271.84K |
| 2024 | -10.68% | -147.39% | 0.07x | 1.09x | $-1.28 Million |
Industry Comparison
This section compares iTonic Holdings Ltd.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| iTonic Holdings Ltd. (ITOC) | $4.73 Million | 20.17% | 0.08x | $3.08K |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |